Aribiolab: Pre-Revenue Losses, Heavy Financing Activity and a Model Estimate Far Below the Share Price

Thesis

The data supports a picture of a company valued on expectations rather than current earnings. Revenue over the last twelve months to H1 2026 was only ₩173M, against an operating loss of ₹13.0B, so the market cap of ₩112.9B is not backed by current sales or profit.

The share price is up 54.8% over three months and 53.8% over one year, but down 3.1% over the past month. It trades well above the 52-week low of ₩1,824 and below the high of ₩6,720.

September and October filings show a rights offering, several convertible bond decisions with amendments, and a change of largest shareholder. These point to active capital raising and ownership changes, though the data does not say what the funds are for or what terms apply. No news headlines are available in the data, so there is no external explanation for the price move.

Business overview

Aribiolab is listed on KOSDAQ in the Biotech & Pharma sector. It was founded on 2000-06-09 and listed on 2021-10-22, with 28,955,976 listed shares and a market cap of ₩112.9B. The CEO is listed as 정재준.

Revenue has been small and uneven: ₩500M in 2021, ₩179M in 2022, ₩294M in 2023, ₩371M in 2024 and ₩159M in 2025. Foreign ownership is 0.1%, up from 0.0% sixty days earlier. Information on products or pipeline is not available in the data.

Model estimate of fair value

Bear

₩220

-94%

Base

₩214

-94%

Bull

₩206

-94%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• Securities Issuance Results (Voluntary Disclosure)Oct 16, 2026
• Material Matters Report (Sale of Own Convertible Bonds Decision)Oct 16, 2026
• Major management matter relevant to investorsOct 6, 2026
• Decision to Acquire Equity-Linked BondsSep 29, 2026
• Amended: Convertible bond issue decisionSep 28, 2026
• Securities Issuance Results (Voluntary Disclosure)Sep 22, 2026
• Amended: Convertible bond issue decisionSep 22, 2026
• Amended: Rights offering (paid-in capital increase) decisionSep 16, 2026
• 5%+ holding reportSep 16, 2026
• Rights offering (paid-in capital increase) decisionSep 16, 2026
• Convertible bond issue decisionSep 14, 2026
• Amended: Change of largest shareholderSep 9, 2026
• Daily prices up to 2026-10-16
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 21, 2026Update noteModel fair value changeAribiolab: Model Fair Value Estimate Rises to ₩567 per Share, Still Far Below Market Price
2. Oct 18, 2026InitiationStart of coverage (reader request)Aribiolab: Pre-Revenue Losses, Heavy Financing Activity and a Model Estimate Far Below the Share Price